Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Jun. 30, 2025
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | During the quarter ended June 30, 2025, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Regulation S-K Item 408, except as follows: • On April 24, 2025, Eyal C. Attar, M.D., the Company’s former Chief Medical Officer, terminated a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of 9,478 shares of common stock between June 3, 2024 and June 30, 2025 (the “Sales Period”) plus up to 36,562 additional shares of common stock that may be acquired by Dr. Attar in connection with the settlement of restricted stock units during the Sales Period, net of shares withheld to satisfy tax withholding obligations, so long as the market price of the Company’s common stock is higher than certain minimum thresholds specified in the trading plan. |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Eyal C. Attar | |
| Trading Arrangements, by Individual | |
| Name | Eyal C. Attar |
| Title | Chief Medical Officer |
| Rule 10b5-1 Arrangement Terminated | true |
| Termination Date | April 24, 2025 |
| Aggregate Available | 9,478 |